Express Delivers Positive Results from Pivotal Clinical Trial of Oral CGRP Receptor Antagonist for Migraine Patients in Asia Pacific

▎WuXi AppTec Content Team Editors On February 14, 2022, Biohaven Pharmaceutical and Pfizer announced positive top-line results from a Phase 3 clinical trial of rimegepant in adults with acute migraine
.

Rimegepant is a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved by the US FDA for both acute treatment of migraine attacks and as a preventive treatment to reduce the frequency of migraine attacks.
Nurtec
.

According to the press release, rimegepant is the first oral CGRP receptor antagonist to achieve positive results in a pivotal clinical trial in the Asia-Pacific region
.

Migraine is a very common chronic disease
.

According to the World Health Organization (WHO), one in ten people in the world suffers from migraine, and women suffer three times as often as men
.

Patients often experience flare-ups with symptoms including headache, photophobia, phonophobia, hallucinations, and nausea
.

Small-molecule CGRP receptor inhibitors represent a new class of drugs for the treatment of migraine, and the activity of CGRP is thought to pathologically contribute to migraine
.

Rimegepant's fast-dissolving oral tablet formulation works by blocking CGRP receptors
.

This is the fourth Phase 3 clinical trial of rimegepant for the acute treatment of migraine, and the first in the Asia-Pacific region, led by BioShin, a wholly-owned subsidiary of Biohaven in the Asia-Pacific region.

.

The trial met its co-primary endpoints of no pain and no most bothersome migraine-related symptoms (MBS, including nausea, phonophobia, or photophobia)
.

A single oral dose of 75 mg rimegepant significantly relieved migraine symptoms and returned patients to normal function within 2 hours
.

Also, the drug provides sustained efficacy for up to 48 hours in many patients
.

In terms of safety, rimegepant showed a favorable safety and tolerability profile, consistent with the results of previous clinical trials in the United States
.

Detailed data from the study will be presented at a future medical meeting
.

Dr.
Vlad Coric, Chief Executive Officer and Chairman of the Board of Directors of Biohaven, commented: "These top-line trial results clearly demonstrate the consistent clinical performance of rimegepant in migraine relief and recovery of patients' normal function
.

Through our partnership with Pfizer, we have Committed to rapidly expanding the accessibility of rimegepant to patients around the world
.

Migraine is a common condition and a leading cause of disability, especially in the Asia Pacific region
.

" Nick Lagunowich, Global President, Pfizer Internal Medicine, said: "Seeing rimegepant It is very exciting to see the successful completion of the first Phase 3 clinical trial in Asia Pacific with positive results
.

Millions of patients in the region are affected by this debilitating neurological disease, and these results provide a hope for patients in need.
hope for a potentially effective novel acute treatment
.

"Reference: [1] Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea.
Retrieved February 14, 2022, from https:// releases/biohaven-and-pfizer-announce-positive-topline-results-of-pivotal-trial-of-rimegepant-for-the-acute-treatment-of-migraine-in-china-and-south-korea-301481322.
html Disclaimer: The WuXi AppTec content team focuses on introducing the progress of global biomedical health research
.

This article is for information exchange purposes only.
The views in this article do not represent WuXi AppTec's position, nor do they support or oppose the views in the article
.

This article is not Recommended treatment plan
.

If you need treatment plan guidance, please go to a regular hospital for treatment
.